Skip to content

Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis

Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02759497
Enrollment
100
Registered
2016-05-03
Start date
2016-03-31
Completion date
2020-11-30
Last updated
2017-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Bacterial Peritonitis

Brief summary

One of the most common and serious complications in decompensated cirrhotic patients (DCPs) is bacterial infection.The most common infections in DCPs are cases of spontaneous bacterial peritonitis (SBP), which account for 40% 70% of cases, followed by urinary tract infections, pneumonia and cellulitis. Serum amyloid A (SAA) and C-reactive protein (CRP) are acute-phase proteins predominantly produced and secreted by hepatocytes. Other cells including lymphocytes, monocytes, and macrophages can also produce these proteins. The induction of SAA and CRP synthesis is triggered by a number of cytokines, chiefly IL-6, which is released from a variety of cell types, but mainly from macrophages and monocytes at inflammatory sites

Detailed description

Increased serum CRP and SAA levels have been found in a number of disorders, including bacterial infections, malignancies tissue injuries and tissue rejection. Therefore, new studies of early diagnosis, prevention and treatment are needed to improve clinical outcomes.

Interventions

serum amyloid A level (SAA)

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* • Decompansated cirrhosis with ascites, defined by a combination of any of the following: * Laboratory findings * Endoscopic results * Ultrasound * Histology

Exclusion criteria

* Creatinine\>1.5 mg/dl * Other infection e.grespiratory,UTI ,gastrointestinal and skin infection. * Hepatocellular carcinoma * Other extrahepatic malignancy e.g ; chest * Any significant psychiatric illness or other medical comorbidity. * Any degenerative diseases.

Design outcomes

Primary

MeasureTime frame
Number of patients with elevated serum amyloid A6months

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, Consultant
sheriefabdelsalam@yahoo.com00201095159522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026